Appointments: New Executives At GSK, Leo Pharma, Valeant, Verona, Ocugen And Peptinnovate
This week’s crop of executive appointments include confirmation that GSK’s new pharma head will start work in September, a new head of Leo Pharma’s US business, and a head of investor relations at Valeant.
You may also be interested in...
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
GlaxoSmithKline's executive team outlined the progress the company is making against COVID-19, lupus nephritis, ovarian cancer and multiple myeloma.
GlaxoSmithKline’s third quarter results included a 9% decline in sales in its vaccine business, but this was offset by tight cost controls and restructuring benefits; the company expects to continue investing in its pipeline and new product launches.